Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026)
Biogen (BIIB) posted quarterly Amortizatization of Intangibles of $107.6 million for Q1 2026, up 109.34% year-over-year from $51.4 million in Q1 2025, and up 42.71% on a QoQ basis from $75.4 million in Q4 2025.
Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Biogen (BIIB) has reported Amortizatization of Intangibles for 4 consecutive years, with $107.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 109.34% year-over-year to $107.6 million; the TTM figure through Mar 2026 stood at $297.0 million (up 25.16% YoY), while the FY2025 annual figure was $240.8 million, up 4.7% from the prior year.
- Amortizatization of Intangibles came in at $107.6 million for Q1 2026 at Biogen, up from $75.4 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $107.6 million in Q1 2026, with the low at $31.5 million in Q4 2023.
- Average Amortizatization of Intangibles over 4 years is $61.0 million, with a median of $52.0 million recorded in 2025.
- Across the five-year window, Amortizatization of Intangibles plunged 41.73% in 2025 and jumped 109.34% in 2026, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $31.5 million in 2023, then jumped by 42.54% to $44.9 million in 2024, then surged by 67.93% to $75.4 million in 2025, then soared by 42.71% to $107.6 million in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $107.6 million, $75.4 million, and $61.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 1.70 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 107.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.60 Mn |
| Mar 31, 2026 | 107.60 Mn |
| Dec 31, 2025 | 75.40 Mn |
| Dec 31, 2025 | 75.40 Mn |
| Sep 30, 2025 | 61.50 Mn |
| Sep 30, 2025 | 61.50 Mn |
| Jun 30, 2025 | 52.50 Mn |
| Jun 30, 2025 | 52.50 Mn |
| Mar 31, 2025 | 51.40 Mn |
| Mar 31, 2025 | 51.40 Mn |
| Dec 31, 2024 | 44.90 Mn |
| Dec 31, 2024 | 44.90 Mn |
| Sep 30, 2024 | 50.90 Mn |
| Sep 30, 2024 | 50.90 Mn |
| Jun 30, 2024 | 90.10 Mn |
| Jun 30, 2024 | 90.10 Mn |
| Mar 31, 2024 | 44.10 Mn |
| Mar 31, 2024 | 44.10 Mn |
| Dec 31, 2023 | 31.50 Mn |
| Dec 31, 2023 | 31.50 Mn |